DOCSLIB.ORG

Illuminating the Role of Shared Decision-Making As the Hemophilia a Management Landscape Continues to Evolve: Progress in Practice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Illuminating the Role of Shared Decision-Making As the Hemophilia a Management Landscape Continues to Evolve: Progress in Practice CME Illuminating the Role of Shared Decision-Making as the Hemophilia A Management Landscape Continues to Evolve: Progress in Practice Course Director and Moderator Guy Young, MD Children's Hospital Los Angeles University of Southern California Keck School of Medicine Los Angeles, California Faculty Rebecca Kruse-Jarres, MD, MPH Washington Center for Bleeding Disorders Bloodworks Northwest Seattle, Washington Faculty Johannes Oldenburg, MD, PhD University Clinic Bonn Bonn, Germany What’s Inside 3 Introduction 6 Innovations in Hemophilia A Therapy: Current Status and Future Directions for Nonfactor Replacement Strategies 17 Extended Half-Life Replacement Clotting Factors for Hemophilia A: What Is Their Clinical Utility? 23 Shared Decision-Making: What Is Its Role in Hemophilia A Management? 31 Q&A and Concluding Remarks Participate in interactive questions, download activity slides, and obtain your instant CME credit online. This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. www.peerview.com/VEQ900 Activity Information Activity Description and Educational Objectives Johannes Oldenburg, MD, PhD In this activity, based on a recent satellite symposium at the 59th American Society of University Clinic Bonn Hematology Annual Meeting and Exposition (ASH 2017), experts in the management of Bonn, Germany hemophilia A consider the role of modified replacement clotting factors in the modern management of patients with this secondary hemostasis disorder, assess the potential Johannes Oldenburg, MD, PhD, has a financial interest/relationship or affiliation in the clinical impact of emerging nonfactor replacement strategies on the future management form of: of individuals with hemophilia A with and without inhibitors, and explore the growing Grant/Research Support from Baxter; Bayer; Biotest Pharmaceuticals Corporation; CSL need for shared decision-making with patients and their families as the number of Behring; Grifols; Novo Nordisk; Octapharma; Pfizer, Inc. therapeutic options continues to expand. The current evidence on each of these topics is Speakers Bureau participant with Baxter; Bayer; Biogen; Biotest Pharmaceuticals reviewed and accompanied by a discussion among the faculty panelists with respect to Corporation; Chugai Pharmaceutical Co., Ltd.; CSL Behring; F. Hoffmann-La Roche; Grifols; the practical applications of this information. Novo Nordisk; Octapharma; Pfizer, Inc.; and Swedish Orphan Biovitrum AB. Advisory Board for Baxter; Bayer; Biogen; Biotest Pharmaceuticals Corporation; Chugai Upon completion of this activity, participants should be better able to: Pharmaceutical Co., Ltd.; CSL Behring; F. Hoffmann-La Roche; Grifols; Novo Nordisk; • Apply key data on recent advances in replacement clotting factor technology when Octapharma; Pfizer, Inc.; and Swedish Orphan Biovitrum AB. managing patients with hemophilia A Johannes Oldenburg, MD, PhD, does intend to discuss either non-FDA-approved or • Analyze recent data on the efficacy, safety, and tolerability of emerging nonfactor investigational use for the following products/devices: therapies for the management of replacement strategies for the management of hemophilia A with and without hemophilia A. inhibitors • Identify the potential utility and impact of emerging nonfactor replacement strategies CME Reviewer on the treatment of hemophilia A with and without inhibitors Amer Assal, MD • Develop strategies designed to facilitate shared decision-making and maintain a Columbia University Medical Center therapeutic alliance with patients with hemophilia A and their caregivers and/or Blood and Marrow Transplantation Program families New York, New York Target Audience Amer Assal, MD, has no financial interests/relationships or affiliations in relation to this This activity has been designed to meet the educational needs of hematologists, activity. hematologist-oncologists, and other clinicians involved in the management of hemophilia. Medical Director Requirements for Successful Completion Kirk A. Tacka, PhD In order to receive credit, participants must view the activity and complete the post-test PVI, PeerView Institute for Medical Education and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME Kirk A. Tacka, PhD, has no financial interests/relationships or affiliations in relation to this credit. Statements of Credit are awarded upon successful completion of the post-test and activity. evaluation form. Disclaimer Media: Enduring Material The information provided at this CME activity is for continuing education purposes only Release and Expiration Dates: December 27, 2017 - December 26, 2018 and is not meant to substitute for the independent medical judgment of a healthcare Time to Complete: 120 minutes provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on Faculty & Disclosure / Conflict of Interest Policy the best available scientific evidence and current clinical guidelines. No bias towards or Before the activity, all faculty and anyone who is in a position to have control over the promotion for any agent discussed in this program should be inferred. content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest Providership, Credit & Support producing healthcare goods/services to be discussed during their presentation(s): This activity has been planned and implemented in accordance with the accreditation honoraria, expenses, grants, consulting roles, speakers bureau membership, stock requirements and policies of the Accreditation Council for Continuing Medical Education ownership, or other special relationships. Presenters will inform participants of any (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in by the ACCME to provide continuing medical education for physicians. the materials or used as the basis for content, and appropriateness of patient care recommendations. The Medical Learning Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with The associates of Medical Learning Institute, Inc., the accredited provider for this activity, the extent of their participation in the activity. and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content Providership of this CME activity during the past 12 months. This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Course Director and Moderator Guy Young, MD Support Director, Hemostasis and Thrombosis Center This activity is supported by an educational grant from Genentech. Children's Hospital Los Angeles Professor of Pediatrics Disclosure of Unlabeled Use University of Southern California Keck School of Medicine The faculty of this educational activity may include discussions of products or devices Los Angeles, California that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Guy Young, MD, has a financial interest/relationship or affiliation in the form of: Honoraria from Bioverativ Inc.; CSL Behring; and Grifols. No endorsement of unapproved products or uses is made or implied by coverage of these Advisory Board for Bayer Corporation; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Kedrion products or uses in our reports. No responsibility is taken for errors or omissions in reports. Biopharma Inc.; Novo Nordisk A/S; and Shire. For approved prescribing information, please consult the manufacturer’s product labeling. Guy Young, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: therapies for the management of hemophilia A. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its Faculty partners, providers, and/or supporters. Rebecca Kruse-Jarres, MD, MPH Director, Washington Center for Bleeding Disorders About This CME Activity Bloodworks Northwest PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are Seattle, Washington responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved Rebecca Kruse-Jarres, MD, MPH, has a financial interest/relationship or affiliation in the products or uses of these products in certain jurisdictions. The preparation of PeerView form of: activities is supported by educational grants subject to written agreements that clearly Consultant for Baxalta/Shire; CSL Behring; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and stipulate and enforce the editorial
Load more

Recommended publications
  • Australian Public Assessment for Efmoroctocog Alfa (Rhu)
    Australian Public Assessment Report 1 for efmoroctocog alfa (rhu) Proprietary Product Name: Eloctate Sponsor: Biogen Idec Australia Pty Ltd January 2015 1 The non-proprietary name has changed post registration from efraloctocog alfa to efmoroctocog afla to harmonise with the International Non-proprietary Name. Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <http://www.tga.gov.au>. About AusPARs · An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time.
    [Show full text]
  • The Potential Role of Recombinant Activated FVII in the Management of Critical Hemato-Oncological Bleeding: a Systematic Review
    Bone Marrow Transplantation (2007) 39, 729–735 & 2007 Nature Publishing Group All rights reserved 0268-3369/07 $30.00 www.nature.com/bmt REVIEW The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review M Franchini1, D Veneri2 and G Lippi3 1Servizio di Immunoematologia e Trasfusione – Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy; 2Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Universita` di Verona, Verona, Italy and 3Dipartimento di Scienze Biomediche e Morfologiche, Istituto di Chimica e Microscopia Clinica, Universita` di Verona, Verona, Italy Recombinant activated factor VII (rFVIIa) is an hemo- situations unresponsive to conventional therapy to control static agent that was originally developed for the excessive bleeding and reduce exposure to allogeneic blood. treatment of hemorrhage in patients with hemophilia and These include intracerebral hemorrhage, oral anticoagu- inhibitors.However, in the last few years rFVIIa has been lant-induced hemorrhage, thrombocytopenia, bleeding employed with success in a broad spectrum of congenital associated with hepatic failure, major surgery, trauma and acquired bleeding conditions.In this systematic review and life-threatening obstetrical, and gynecologic hemor- we present the current knowledge on the use of this drug in rhagic complications.5–9 patients suffering from hemato-oncological disorders, In this systematic review we have collected the available which are quite commonly complicated by severe hemor- data from the literature on the use of rFVIIa in hemato- rhage.On the whole, data in the literature suggest a oncological patients with severe bleeding, unresponsive to potential role for rFVIIa in the management of bleeding standard therapy.
    [Show full text]
  • Human and Recombinat Coagulation Factor VIII
    08 July 2016 EMA/PRAC/471535/2016 PRAC List of questions To be addressed by the marketing authorisation holder(s) for human and recombinant coagulation factor VIII containing medicinal products Referral under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data Procedure number: EMEA/H/A-31/1448 Advate EMEA/H/C/0520/A31/0078 Elocta EMEA/H/C/3964/A31/0006 Helixate Nexgen EMEA/H/C/0276/A31/0178 Iblias EMEA/H/C/4147/A31/0002 Kogenate EMEA/H/C/0275/A31/0185 Kovaltry EMEA/H/C/3825/A31/0004 Novoeight EMEA/H/C/2719/A31/0014 Nuwiq EMEA/H/C/2813/A31/0015 Obizur EMEA/H/C/2792/A31/0003 Refacto AF EMEA/H/C/0232/A31/0134 Voncento EMEA/H/C/2493/A31/0022 Active substances: human coagulation factor VIII; efmoroctocog alfa; moroctocog alfa; octocog alfa; simoctocog alfa; susoctocog alfa; turoctocog alfa 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 1. Background Today’s standard treatment of congenital haemophilia (and acquired haemophilia A) is based on prophylactic or on-demand replacement therapy with coagulation factor VIII (FVIII), either with plasma derived or with recombinant FVIII products. Principally both substance classes may be used for prophylactic treatment as well as for therapeutic treatment in case of spontaneous bleedings. Inhibitor development in haemophilia A patients receiving FVIII products mostly occurs in previously untreated or minimally treated patients (PUPs), who are still within the first 50 days of exposure to the treatment.
    [Show full text]
  • Multiple Technology Appraisal Avatrombopag and Lusutrombopag
    Multiple Technology Appraisal Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Committee papers © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE MULTIPLE TECHNOLOGY APPRAISAL Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Contents: 1 Pre-meeting briefing 2 Assessment Report prepared by Kleijnen Systematic Reviews 3 Consultee and commentator comments on the Assessment Report from: • Shionogi 4 Addendum to the Assessment Report from Kleijnen Systematic Reviews 5 Company submission(s) from: • Dova • Shionogi 6 Clarification questions from AG: • Questions to Shionogi • Clarification responses from Shionogi • Questions to Dova • Clarification responses from Dova 7 Professional group, patient group and NHS organisation submissions from: • British Association for the Study of the Liver (BASL) The Royal College of Physicians supported the BASL submission • British Society of Gastroenterology (BSG) 8 Expert personal statements from: • Vanessa Hebditch – patient expert, nominated by the British Liver Trust • Dr Vickie McDonald – clinical expert, nominated by British Society for Haematology • Dr Debbie Shawcross – clinical expert, nominated by Shionogi © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. MTA: avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure Pre-meeting briefing © NICE 2019.
    [Show full text]
  • PRESS RELEASE Stockholm, Sweden, 8 July 2020
    PRESS RELEASE Stockholm, Sweden, 8 July 2020 Data to be presented at ISTH Virtual Congress highlights Sobi´s commitment to advancing rare haematology treatments Sobi™ will present data at the ISTH Virtual Congress (International Society on Thrombosis and Haemostasis), 12 – 14 July 2020, strengthening evidence for the efficacy and safety of Elocta® (efmoroctocog alfa) and Alprolix® (eftrenonacog alfa), for haemophilia A and B respectively, as well as pharmacokinetic data on BIVV001 (rFVIIIFc-VWF-XTEN). Data for Doptelet® (avatrombopag) in treatment for thrombocytopenia within Chronic Liver Disease (CLD) and Chronic Immune Thrombocytopenia (ITP) will be presented. Final data in previously untreated patients with haemophilia Final data from the long-term studies: PUPs A-LONG and PUPs B-LONG in previously untreated patients (PUP) with haemophilia A and B, treated with Elocta and Alprolix will be presented in collaboration with Sanofi. Factor replacement therapy remains a cornerstone of haemophilia management and data shared in presentations will add to a growing body of clinical evidence for rFVIIIFc and rFIXFc, extended half-life factor therapies for haemophilia A and B, respectively. Oral Communication • Final results of the PUPs A-LONG Study: Evaluating Safety and Efficacy of rFVIIIFc in Previously Untreated Patients with Haemophilia A. Oral communication #OC 03.2. Sunday, July 12, 2020 from 10:15 – 11:30 EDT (16.15-17.30 CET) (Joint with Sanofi) Abstracts • Final Results of PUPs B-LONG Study: Evaluating Safety and Efficacy of rFIXFc in Previously Untreated Patients with Haemophilia B. Poster presentation # PB0956. (Joint with Sanofi) • A French Multicentre Prospective, Non-Interventional Study (B-SURE) Evaluating Real-World Usage and Effectiveness of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in People with Haemophilia B: Baseline Data.
    [Show full text]
  • Australian Public Assessment Report for Lonoctocog Alfa (Rch)
    Australian Public Assessment Report for lonoctocog alfa (rch) Proprietary Product Name: Afstyla Sponsor: CSL Behring Australia Pty Ltd January 2018 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs · An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. · An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61L 27/58 (2006.01) A61L 27/52 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 14/028622 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 14 March 2014 (14.03.2014) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/785,477 14 March 2013 (14.03.2013) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicant: MEDICUS BIOSCIENCES LLC [US/US]; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 2528 Qume Dr., Unit #1, San Jose, CA 95 13 1 (US).
    [Show full text]
  • Justification
    Justification to the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM ‑ RL): Annex XII – Resolutions on the Benefit Assessment of Medicinal Products with New Active Ingredients in Accordance with Section 35a SGB V Damoctocog alfa pegol From 20 June 2019 Contents 1. Legal basis ................................................................................................................ 2 2. Key points of the resolution ..................................................................................... 2 2.1 Additional benefit of the medicinal product in relation to the appropriate comparator therapy ..................................................................................................... 3 2.1.1 Approved therapeutic indication of damoctocog alfa pegol (Jivi®) in accordance with the summary of product characteristics ............................................ 3 2.1.2 Appropriate comparator therapy ................................................................... 3 2.1.3 Extent and probability of the additional benefit .............................................. 5 2.1.4 Summary of the assessment ........................................................................ 6 2.2 Number of patients or demarcation of patient groups eligible for treatment ...... 6 2.3 Requirements for a quality-assured application ................................................ 7 2.4 Treatment costs ..............................................................................................
    [Show full text]
  • Dossier Zur Nutzenbewertung Gemäß § 35A SGB V
    Dokumentvorlage, Version vom 16.08.2018 Dossier zur Nutzenbewertung gemäß § 35a SGB V Turoctocog alfa pegol (Esperoct®) Novo Nordisk Pharma GmbH Modul 3 A Behandlung und Prophylaxe von Blutungen bei Patienten im Alter von 12 Jahren und älter mit Hämophilie A (angeborener Faktor VIII-Mangel). Zweckmäßige Vergleichstherapie, Anzahl der Patienten mit therapeutisch bedeutsamem Zusatznutzen, Kosten der Therapie für die GKV, Anforderungen an eine qualitätsgesicherte Anwendung Stand: 30.07.2019 Dossier zur Nutzenbewertung – Modul 3 A Stand: 30.07.2019 Vergleichstherapie, Patienten mit therap. bedeutsamem Zusatznutzen, Kosten, qualitätsgesicherte Anwendung Inhaltsverzeichnis Seite Tabellenverzeichnis .................................................................................................................. 2 Abbildungsverzeichnis ............................................................................................................. 4 Abkürzungsverzeichnis ............................................................................................................ 5 3 Modul 3 – allgemeine Informationen ............................................................................ 7 3.1 Bestimmung der zweckmäßigen Vergleichstherapie .................................................... 8 3.1.1 Benennung der zweckmäßigen Vergleichstherapie ................................................ 9 3.1.2 Begründung für die Wahl der zweckmäßigen Vergleichstherapie .......................... 9 3.1.3 Beschreibung der Informationsbeschaffung für Abschnitt
    [Show full text]
  • Beverly, A., Ong, G., Wilkinson, KL, Doree, C., Welton, NJ, & Estcourt, LJ
    Beverly, A., Ong, G., Wilkinson, K. L., Doree, C., Welton, N. J., & Estcourt, L. J. (2019). Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: A systematic review and network meta analysis. Cochrane Database of Systematic Reviews, 2019(9), [CD013427]. https://doi.org/10.1002/14651858.CD013427 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD013427 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Collaboration at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013427/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Cochrane Database of Systematic Reviews Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta- analysis (Protocol) Beverly A, Ong G, Wilkinson KL, Doree C, Welton NJ, Estcourt LJ Beverly A, Ong G, Wilkinson KL, Doree C, Welton NJ, Estcourt LJ. Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD013427. DOI: 10.1002/14651858.CD013427. www.cochranelibrary.com Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta-analysis (Protocol) Copyright © 2019 The Cochrane Collaboration.
    [Show full text]
  • Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis
    International Journal of Molecular Sciences Review Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis Vassilios P. Memtsas 1, Deepa R. J. Arachchillage 2,3,4 and Diana A. Gorog 1,5,6,* 1 Cardiology Department, East and North Hertfordshire NHS Trust, Stevenage, Hertfordshire SG1 4AB, UK; [email protected] 2 Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London SW7 2AZ, UK; [email protected] 3 Department of Haematology, Imperial College Healthcare NHS Trust, London W2 1NY, UK 4 Department of Haematology, Royal Brompton Hospital, London SW3 6NP, UK 5 School of Life and Medical Sciences, Postgraduate Medical School, University of Hertfordshire, Hertfordshire AL10 9AB, UK 6 Faculty of Medicine, National Heart and Lung Institute, Imperial College, London SW3 6LY, UK * Correspondence: [email protected]; Tel.: +44-207-0348841 Abstract: Diseases such as myocardial infarction, ischaemic stroke, peripheral vascular disease and venous thromboembolism are major contributors to morbidity and mortality. Procoagulant, anticoagulant and fibrinolytic pathways are finely regulated in healthy individuals and dysregulated procoagulant, anticoagulant and fibrinolytic pathways lead to arterial and venous thrombosis. In this review article, we discuss the (patho)physiological role and laboratory assessment of fibrin, factor XIII and endogenous fibrinolysis, which are key players in the terminal phase of the coagulation cascade and fibrinolysis. Finally, we present the most up-to-date evidence for their involvement in Citation: Memtsas, V.P.; various disease states and assessment of cardiovascular risk. Arachchillage, D.R.J.; Gorog, D.A. Role, Laboratory Assessment and Keywords: factor XIII; fibrin; endogenous fibrinolysis; thrombosis; coagulation Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.
    [Show full text]
  • HTRS 2021 Scientific Symposium PRELIMINARY VIRTUAL MEETING AGENDA
    HTRS 2021 Scientific Symposium PRELIMINARY VIRTUAL MEETING AGENDA HTRS Research Colloquium: March 8-9 FWGBD Colloquium: March 9 Multidisciplinary Pre-Conference: March 10-11 Agenda: Day 1 | Day 2 Agenda Agenda: Day 1 | Day 2 HTRS Scientific Symposium: March 10-12 Agenda: Day 1 | Day 2 | Day 3 MONDAY, MARCH 8, 2021 HTRS Research Colloquium: Day 1 – separate registration required Eastern Time Event 12:30 PM – 1:00 PM ET PRE-MEETING NETWORKING “BRING YOUR OWN LUNCH” 1:00 PM ET OPENING REMARKS Wolfgang Bergmeier, PhD, and Margaret V. Ragni, MD, MPH, 2021 Colloquium Co-Chairs 1:05 PM – 1:50 PM ET PLENARY SESSION: “HOW DO I BEGIN, AND WHO IS GOING TO PAY FOR THIS?” RESEARCH FUNDING TRENDS AND OPPORTUNITIES Moderator: Margaret V. Ragni, MD, MPH Speaker: Andrei Kindzelski, MD, National Institutes of Health (NIH) 1:50 PM – 2:20 PM ET NETWORKING BREAK -OR- MENTORING SESSIONS 2:20 PM – 3:20 PM ET PANEL PRESENTATION: “GETTING A JOB – A RECRUITER’S PERSPECTIVE” Moderator: Wolfgang Bergmeier, PhD 2:20 PM BASIC SCIENCE PERSPECTIVE James Morrissey, PhD, Professor, University of Michigan 2:35 PM CLINICAL SCIENCE PERSPECTIVE Janis Abkowitz, PhD, Professor, Hematology Division Head, University of Washington 1 HTRS Research Colloquium: Day 1 – continued Eastern Time Event 2:50 PM TRANSLATIONAL SCIENCE PERSPECTIVE Jorge Di Paola, MD, Professor/Division Chief, Washington University in St. Louis 3:05 PM INDUSTRY PERSPECTIVE Robert Peters, PhD, Sanofi Genzyme 3:20 PM – 4:00 PM ET ROUNDTABLE DISCUSSIONS • Basic Science Tables • Clinical Science Tables • Translational Science Tables • Population Science Tables 4:00 PM ET DAY ONE PROGRAM ENDS Session resumes Tuesday, March 9 at 12:30 PM ET TUESDAY, MARCH 9, 2021 FWGBD Colloquium on Uterine Hemostasis – separate registration required Eastern Time Event 9:30 AM – 9:45 AM ET CONVENE AND WELCOME Andra H.
    [Show full text]